All HIV articles
-
NewsHIV infections would increase by 10% average if CDC funding for HIV testing ends, study predicts
Researchers used a computer model to quantify the effect of funding cuts for HIV testing. They estimate that HIV infections could increase an average of 10% in 18 U.S. states if this funding is interrupted or ended.
-
NewsSpecific patterns of CD39 expression on T-cells of HIV/HCV coinfected patients receiving antiretroviral therapy
Researchers demonstrated that CD4+ T-cells act as the main regulators of purinergic signals in HIV/HCV coinfected and healthy individuals. At the same time, the proportion of CD4+ T-cells involved in the control of purinergic signaling was increased in HIV/HCV coinfected patients compared with healthy subjects.
-
NewsNew research suggests HIV can be kept in check – without medication
An international study shows that a combination of two parts of the immune system – antibodies and T cells – can suppress HIV without lifelong medication.
-
NewsWhy some people naturally control HIV even after stopping therapy — and how we can leverage that to treat others
New research offers a path toward life without daily HIV pills, suggesting a common diabetes pill could help achieve long-term remission.
-
News How viruses mess with our brains
What impact does a viral infection have on our memory, attention, and concentration? A new review has identified several biological markers associated with cognitive decline in the context of infection. It also provides a solid foundation for future research.
-
NewsNew tool reveals the secrets of HIV-infected cells
Scientists have developed a novel tool—named HIV-seq—for profiling the features of rare HIV-infected cells from people with HIV. Using the new tool, they’ve found key differences in people’s HIV-infected cells before versus after starting antiretroviral therapy.
-
NewsSingle daily pill shows promise as replacement for complex, multi-tablet HIV treatment regimens
A phase 3 clinical trial has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and lenacapavir (BIC/LEN) – may simplify treatment significantly for people with HIV who currently take very complex treatments.
-
NewsNew strategies aim at HIV’s last strongholds
A new study has overcome a long-standing challenge—how to isolate and study elusive HIV-infected cells called authentic reservoir clones (ARCs) that evade the immune system, making the disease difficult to cure.
-
NewsExposing a hidden anchor for HIV replication
Scientists investigating HIV have revealed a previously unknown role for the viral protein integrase, which helps HIV insert itself into human DNA. A new study provides the first direct evidence that integrase plays a critical structural role earlier on in HIV’s life cycle — when the virus matures into an infectious force.
-
NewsHIV antibody opens up new approaches for vaccine development and combination therapies
An international research team has identified a novel HIV antibody that targets the virus at a particularly vulnerable site and overcomes previous limitations of known antibodies. The study opens up new perspectives for the development of vaccines and therapeutics against HIV-1.
-
News
New vaccine platform promotes rare protective B cells
Based on a virus-like particle built with a DNA scaffold, the approach could generate broadly neutralizing antibody responses against HIV or influenza.
-
NewsScientists demonstrate first-ever single-shot HIV vaccine neutralization success
Scientists have developed an HIV vaccine candidate that achieves something never before observed in the field: inducing neutralizing antibodies against HIV after a single immunization in nonhuman primates.
-
NewsSepsis study IDs simple ways to save lives in Africa
Tuberculosis (TB) is a major unrecognized cause of deadly sepsis among people with HIV in Africa, a new study reveals. It found that more than half of the hundreds of patients enrolled in the study had TB and that immediate treatment increased their chances of survival significantly.
-
NewsLithium study yields insights in the fight against HIV
Lithium, a widely used treatment for bipolar disorder and other mood disorders, has shown early promise in suppressing HIV. A new study found lithium can prevent infected cells from reactivating, and that it does so through an unexpected biological mechanism.
-
NewsTB and HIV treatments are not enough for a full recovery
Existing treatments control TB and HIV, but the immune system does not revert to normal, helping explain why people living with HIV remain susceptible to infections and underscoring the need for immunotherapies.
-
NewsReal-world data gives Africa a smarter path to fighting HIV and TB
African biostatisticians have offered a powerful, data-driven alternative that can accurately inform HIV policy, reduce healthcare costs, and save more lives.
-
NewsResearchers see dramatic drop in HIV-infected immune cells in patient after cancer treatment received
Researchers report they may have taken an early step toward a more practical HIV cure. They focused on a patient undergoing cancer treatment and also living with HIV, who after receiving chemotherapy, had a significant reduction in the number of CD4+ T immune cells that contained an HIV provirus.
-
NewsA testing paradox for sexually transmitted infections
Surveillance evidence shows an increase in people infected with other STIs after initiating PrEP. A new study provides a counterintuitive explanation revealing a testing paradox: even when the observed cases increase, the true numbers of STIs can decrease.
-
NewsNew test distinguishes vaccine-induced false positives from active HIV infection
A new device correctly identified those with active HIV-1 infection 95% of the time and those without active infection but with vaccine-induced molecules that could trigger a false positive, 98% of the time.
-
NewsCommon water pill may help HIV medicines work faster and reduce inflammation, early study suggests
Adding a readily available diuretic to standard HIV therapy appears to reduce circulating virus by four-fold, a new study shows. Researchers treated HIV-infected mice with human immune cells with first‑line antiretroviral therapy plus a long‑acting form of spironolactone.